Akari Therapeutics (AKTX) Liabilities and Shareholders Equity (2011 - 2026)

Akari Therapeutics (AKTX) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $33.9 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 33.5% year-over-year to $33.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.1 million (up 62.87% YoY) and the FY2025 annual result came in at $47.9 million, down 5.28% from the prior year.
• Liabilities and Shareholders Equity fell to $33.9 million in Q1 2026 per AKTX's latest filing, from $47.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for AKTX reached as high as $51.0 million in Q1 2025 and fell as low as $2.7 million in Q3 2024.
• A 5-year average of $25.2 million and a median of $13.8 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 68.52% — and 2025, when it surged 1738.35%.
• Year by year, Liabilities and Shareholders Equity stood at $13.8 million in 2022, then tumbled by 68.52% to $4.4 million in 2023, then soared by 1061.01% to $50.6 million in 2024, then dropped by 5.28% to $47.9 million in 2025, then fell by 29.24% to $33.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $33.9 million, $47.9 million, and $45.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.